PRESTIGE CONSUMER HEALTHCARE INC. Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount
PRESTIGE CONSUMER HEALTHCARE INC. (PBH) had Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount of $3.20 million as of 2024-12-31, per its 10-Q filed 2025-02-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized · last filed 2025-02-06
- 2024-12-31: Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $3.20M.
- 2024-09-30: Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $3.80M.
- 2024-06-30: Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $4.50M.
- 2024-03-31: Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $2.70M.
| Period end | Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount |
|---|---|
| 2024-12-31 | $3.20M 10-Q · filed 2025-02-06 |
| 2024-09-30 | $3.80M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $4.50M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $2.70M 10-K · filed 2024-05-15 |
| 2023-12-31 | $3.10M 10-Q · filed 2024-02-08 |
| 2023-09-30 | $3.80M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $4.60M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $3.00M 10-K · filed 2023-05-05 |
| 2022-12-31 | $3.90M 10-Q · filed 2023-02-02 |
| 2022-09-30 | $4.80M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $5.50M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $2.80M 10-K · filed 2022-05-06 |
| 2021-12-31 | $3.20M 10-Q · filed 2022-02-03 |
| 2021-09-30 | $4.00M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $13.10M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $6.60M 10-K · filed 2021-05-07 |
| 2020-12-31 | $7.90M 10-Q · filed 2021-02-04 |
| 2020-09-30 | $9.80M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $11.70M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $6.00M 10-K · filed 2020-05-08 |
| 2019-12-31 | $7.50M 10-Q · filed 2020-02-06 |
| 2019-09-30 | $9.20M 10-Q · filed 2019-10-31 |
| 2019-06-30 | $11.00M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $5.50M 10-K · filed 2019-05-13 |
| 2018-12-31 | $7.60M 10-Q · filed 2019-02-07 |
| 2018-09-30 | $9.40M 10-Q · filed 2018-11-01 |
| 2018-06-30 | $11.30M 10-Q · filed 2018-08-02 |
| 2018-03-31 | $8.20M 10-K · filed 2018-05-10 |
| 2017-12-31 | $8.50M 10-Q · filed 2018-02-01 |
| 2017-09-30 | $10.70M 10-Q · filed 2017-11-02 |
| 2017-06-30 | $12.80M 10-Q · filed 2017-08-03 |
| 2017-03-31 | $7.90M 10-K · filed 2017-05-17 |
| 2016-12-31 | $10.50M 10-Q · filed 2017-02-02 |
| 2016-09-30 | $12.40M 10-Q · filed 2016-11-03 |
| 2016-06-30 | $13.80M 10-Q · filed 2016-08-04 |
| 2016-03-31 | $10.10M 10-K · filed 2016-05-17 |
| 2015-12-31 | $11.60M 10-Q · filed 2016-02-04 |
| 2015-09-30 | $13.30M 10-Q · filed 2015-11-05 |
| 2015-06-30 | $14.50M 10-Q · filed 2015-08-06 |
| 2015-03-31 | $4.90M 10-K · filed 2015-05-14 |
| 2014-12-31 | $5.90M 10-Q · filed 2015-02-05 |
| 2014-09-30 | $7.40M 10-Q · filed 2014-11-06 |
| 2014-06-30 | $8.70M 10-Q · filed 2014-08-07 |
| 2014-03-31 | $3.70M 10-K · filed 2014-05-19 |
| 2013-12-31 | $5.00M 10-Q · filed 2014-02-07 |
| 2013-09-30 | $6.10M 10-Q · filed 2013-11-07 |
| 2013-06-30 | $7.10M 10-Q · filed 2013-08-01 |
| 2013-03-31 | $3.00M 10-K · filed 2013-05-17 |
| 2012-12-31 | $4.00M 10-Q · filed 2013-02-07 |
| 2012-09-30 | $5.00M 10-Q · filed 2012-11-07 |
| 2012-06-30 | $5.90M 10-Q · filed 2012-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |